A naukri.com initiative
Bioengineer
2w
276
Image Credit: Bioengineer
Penn Medicine Showcases Latest Research at the 2025 ASCO Annual Meeting
- Researchers from Penn Medicine will present groundbreaking data at the 2025 ASCO Annual Meeting in Chicago, focusing on cancer science and therapeutic innovation.
- A Phase I trial will showcase a dual-target CAR T cell therapy for recurrent glioblastoma, targeting EGFR and IL13Rα2, with a unique delivery system to bypass the blood-brain barrier.
- Results from the LITEPARK-004 trial on belzutifan for VHL disease reveal significant tumor growth reduction, less need for invasive surgeries, and a shift towards targeted molecular inhibition.
- An investigation on neoadjuvant immunotherapy for early-stage melanoma using pembrolizumab shows a reduction in lymph node metastasis, especially in stage IIC patients.
- Studies at the Basser Center for BRCA highlight digital interventions for genetic counseling and a DNA plasmid vaccine for BRCA mutation carriers, showing promising safety and feasibility.
- Penn Medicine's efforts integrate precision medicine, immunoengineering, and digital health to personalize cancer prevention and treatment, anticipating improved patient outcomes.
- The ASCO 2025 meeting will engage oncology experts in discussions on advancements like dual-target CAR T therapy and belzutifan's sustainable impact on VHL disease.
- Melanoma immunotherapy challenges provide insights into optimizing treatment strategies based on biomarkers, emphasizing the need for tailored approaches at different disease stages.
- Utilizing digital tools for genetic testing aims to enhance access to precision oncology globally, with hybrid models offering scalable solutions for genetic counseling.
- The DNA plasmid vaccine trial in BRCA mutation carriers pioneers a proactive approach to cancer interception through immune system engagement before tumor development.
Read Full Article
16 Likes
For uninterrupted reading, download the app